Prof Ghosh presented data from the UNITI studies exploring ustekinumab in primary or secondary nonresponders to TNF agonists (UNITI-1) and conventional therapy failures (UNITI-2).
Latest articles
All articles



We’ve noticed you’re accessing
from North/South America.
from North/South America.